Marked improvement by high-dose chemotherapy and autologous stem cell transplantation in a case of light chain deposition disease

Journal of Nephrology

Volumn 24, Issue 2, 2011, Pages 246-249

  Matsuzaki, Keiichi ^a   Ohsawa, Isao ^a   Nishitani, Tomohito ^a   Takeda, Yukihiko ^a   Inoshita, Hiroyuki ^a   Ishii, Masaya ^a   Takagi, Miyuki ^a   Horikoshi, Satoshi ^a   Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Autologous stem cell transplantation; Light chain deposition disease (LCDD); Nephrotic syndrome; Plasma cell dyscrasia

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN KAPPA CHAIN; PREDNISOLONE; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CASE REPORT; DISEASE CONTROL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GLOMERULOSCLEROSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY BIOPSY; LIGHT CHAIN DEPOSITION DISEASE; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; NODULAR GLOMERULOSCLEROSIS; PLASMA CELL DYSCRASIA; PROTEINURIA; SYSTEMIC DISEASE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BOWMAN CAPSULE; COMBINED MODALITY THERAPY; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; KIDNEY TUBULES, PROXIMAL; MIDDLE AGED; NEPHROTIC SYNDROME; PARAPROTEINEMIAS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VINCRISTINE;

EID: 79953700268     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2011.6241     Document Type: Article

References (12)

1. Randall RE, Williamson WC Jr, Mullinax F, Tung MY, Still WJ. Manifestations of systemic light chain deposition. Am J Med. 1976;69:703-710.
2. Royer B, Arnulf B, Martinez F, et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int. 2004;65:642-648.
3. Lorenz EC, Gertz MA, Fervenza FC, et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant. 2008;23:2052-2057.
4. Gerth J, Busch M, Ott U, et al. Evolution of light chain deposition disease over 8 years. Clin Nephrol. 2009;72:397-401.
5. Adam Z, Krejci M, Pour L, et al. Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells: a case study and review of literature. Vnitr Lek. 2009;55:1089-1096.
6. Adam Z, Nedbalkova M, Krejci M, et al. More than 10 years of complete remission of monoclonal gammopathy of undetermined significance and cessation of chain deposition disease-associated nephritic syndrome following treatment with vincristine, adriamycin and high-dose dexamethasone (VAD). Vnitr Lek. 2010;56:240-246.
7. Jennette JC, Olson JL, Schwartz MM, Silva FG, eds. Heptinstall's pathology of the kidney. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:869-875.
8. Pozzi C, D'Amico M, Fogazzi GB, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003;42:1154-1163.
9. Joh K. Pathology of glomerular deposition diseases. Pathol Int. 2007;57:551-565.
10. Lin J, Markowitz GS, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol. 2001;12:1482-1492.
11. Petrakis I, Stylianou K, Marvoeidi V, et al. Biopsy-proven resolution of renal light-chain deposition disease after autologous stem cell transplantation. Nephrol Dial Transplant. 2010;25:2020-2023.
12. Okura T, Miyoshi K, Nagao T, et al. Light chain deposition disease developing 15 years following the diagnosis of monoclonal gammopathy of undetermined significance. Intern Med. 2009;48:101-104.